BACKGROUND: Topotecan activity was evaluated for the treatment of malignant glioma. METHODS: Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan [AU: Please verify all dosages here and throughout text.]at a dose of 2.6 mg/m2 over a 72-hour period weekly. Recurrent tumors included glioblastoma multiforme (GBM) (n = 28) and anaplastic astrocytoma (AA) (n = 10). Newly diagnosed tumors included GBM (n = 14), AA (n = 8), and anaplastic oligodendroglioma (n = 3). RESULTS: Partial responses were observed in 2 of 14 evaluable patients with newly diagnosed GBM, 1 of 8 patients with newly diagnosed AA, 3 of 10 patients with recurrent AA, and none of 28 patients with recurrent GBM. Four patients with recurrent AA and 7 patients with recurrent GBM demonstrated stable disease (range, 8-52 weeks; median, 21 weeks). Toxicity was limited to infrequent National Cancer Institute Common Toxicity Criteria Grade 3 myelosuppression. CONCLUSIONS: These results suggest that topotecan has modest activity against malignant glioma and continued evaluation of its effectiveness may be warranted when alternative schedules or combination regimens are used.
BACKGROUND:Topotecan activity was evaluated for the treatment of malignant glioma. METHODS: Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan [AU: Please verify all dosages here and throughout text.]at a dose of 2.6 mg/m2 over a 72-hour period weekly. Recurrent tumors included glioblastoma multiforme (GBM) (n = 28) and anaplastic astrocytoma (AA) (n = 10). Newly diagnosed tumors included GBM (n = 14), AA (n = 8), and anaplastic oligodendroglioma (n = 3). RESULTS: Partial responses were observed in 2 of 14 evaluable patients with newly diagnosed GBM, 1 of 8 patients with newly diagnosed AA, 3 of 10 patients with recurrent AA, and none of 28 patients with recurrent GBM. Four patients with recurrent AA and 7 patients with recurrent GBM demonstrated stable disease (range, 8-52 weeks; median, 21 weeks). Toxicity was limited to infrequent National Cancer Institute Common Toxicity Criteria Grade 3 myelosuppression. CONCLUSIONS: These results suggest that topotecan has modest activity against malignant glioma and continued evaluation of its effectiveness may be warranted when alternative schedules or combination regimens are used.
Authors: Laura P Serwer; Charles O Noble; Karine Michaud; Daryl C Drummond; Dmitri B Kirpotin; Tomoko Ozawa; Michael D Prados; John W Park; C David James Journal: Neuro Oncol Date: 2011-09-27 Impact factor: 12.300
Authors: Adam M Sonabend; R Morgan Stuart; Jonathan Yun; Ted Yanagihara; Hamed Mohajed; Steven Dashnaw; Samuel S Bruce; Truman Brown; Alex Romanov; Manu Sebastian; Fernando Arias-Mendoza; Emilia Bagiella; Peter Canoll; Jeffrey N Bruce Journal: Neuro Oncol Date: 2011-07-12 Impact factor: 12.300
Authors: Jeffrey N Bruce; Robert L Fine; Peter Canoll; Jonathan Yun; Benjamin C Kennedy; Steven S Rosenfeld; Stephen A Sands; Krishna Surapaneni; Rose Lai; Candix L Yanes; Emilia Bagiella; Robert L DeLaPaz Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: P A Burch; A M Bernath; T L Cascino; B W Scheithauer; P Novotny; S Nair; J C Buckner; D M Pfeifle; J W Kugler; L K Tschetter Journal: Invest New Drugs Date: 2000-08 Impact factor: 3.850
Authors: Randy S D'Amico; Justin A Neira; Jonathan Yun; Nikita G Alexiades; Matei Banu; Zachary K Englander; Benjamin C Kennedy; Timothy H Ung; Robert J Rothrock; Alexander Romanov; Xiaotao Guo; Binsheng Zhao; Adam M Sonabend; Peter Canoll; Jeffrey N Bruce Journal: J Neurosurg Date: 2019-08-02 Impact factor: 5.115
Authors: Richard C E Anderson; Benjamin Kennedy; Candix L Yanes; James Garvin; Michael Needle; Peter Canoll; Neil A Feldstein; Jeffrey N Bruce Journal: J Neurosurg Pediatr Date: 2012-12-14 Impact factor: 2.375